• |
The selection represents Innoviz’s first win in Asia, fourth major design win and second consecutive Tier 1 win for series production of passenger vehicles as a direct LiDAR supplier, validating the Company’s strategy to become a
direct supplier.
|
• |
We expect this new win, when combined with the two existing production launches next year, will further support the Company’s ability to grow its revenues meaningfully in the coming years.
|
• |
From a geographic standpoint, the design-win expands Innoviz’s global reach and production footprint in Asia, marking an important step in the Company’s platform expansion efforts. We believe it also strengthens Innoviz’s position with
other Asian OEM’s currently in the Company’s pipeline.
|
• |
The deal also marks the Company’s first production win with a new technology partner. Innoviz now has production wins with two of the industry’s three major autonomous driving technology platform partners, offering an important advantage
over competitors in upcoming customer decision making, as we increasingly become an off-the-shelf solution for OEMs.
|
• |
Following the Company’s recent quarterly business progress, Innoviz is updating its forward-looking order book to $6.9 billion.
|
• |
The Company made significant progress towards series production for customers, moving to the D-sample stage, the final step before the start of production.
|
• |
The Company currently works directly with OEMs representing roughly 15% of the global market.
|
• |
In Q2 2022, Innoviz disclosed 12 programs in the RFI or RFQ process. With the Company’s new Asia-based OEM converted to a full production customer, it now has 11 OEMs in the RFI and RFQ process and expects an additional one to three new
decisions by OEMs in the next six months.
|
• |
Collectively, the 11 OEM’s in the Company’s pipeline produce approximately 40 million vehicles per year, representing an additional roughly 42% of the global market.
|
• |
The Company targeted 10 pre-production programs, one commercial agreement and a 30% increase in its forward-looking order book in 2022. As of September 30, 2022, the Company boasts 14 pre-production programs, two commercial agreements and
a 165% year to date increase in its forward-looking order book.
|
• |
The Company remains on track to introduce the all-new Innoviz360 at CES in January 2023. This breakthrough product is expected to unlock exceptional price and performance metrics for a spinning LiDAR, opening new markets in both the
automotive and non-automotive segments.
|
• |
Kudan, a 3D digital mapping solutions provider for a broad range of applications including HD maps, robotics, construction, surveying, and "digital twinning" and the "industrial metaverse;”
|
• |
Sensagrate, a smart city technology provider that enables real-time traffic, pedestrian and cyclist safety via intersection monitoring and analysis; and
|
• |
HiRain Technologies, a leading technology solution provider for the transportation market in China that provides autonomous trucks and AGVs, as well as Vehicle to Anything (V2X) applications, to improve operational efficiency,
mitigate risks and enhance worker safety.
|
• |
The Company has achieved its stated goal of winning at least one new series production award in 2022, and to date has delivered two.
|
• |
The Company expects to increase its forward-looking order book by more than 30% by the end of 2022 and has already delivered a 165% increase year to date.
|
• |
The Company has achieved its expected stated goal to secure 10 pre-production programs during 2022. To date, the Company has participated in 14.
|
Investor Contact (US)
|
Investor Contact (Israel)
|
Rob Moffatt
|
Maya Lustig
|
VP, Corporate Development & IR
|
Director, Investor Relations
|
Innoviz Technologies
|
Innoviz Technologies
|
+1 (203) 665-8644
|
+972 54 677 8100
|
Investors@innoviz-tech.com
|
Investors@innoviz-tech.com
|
Nine Months Ended
September 30,
|
Three Months Ended
September 30,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
|||||||||||||||
Revenues
|
$
|
4,449
|
$
|
3,811
|
$
|
878
|
$
|
2,076
|
||||||||
Cost of revenues
|
(10,677
|
)
|
(5,737
|
)
|
(4,593
|
)
|
(2,201
|
)
|
||||||||
Gross loss
|
(6,228
|
)
|
(1,926
|
)
|
(3,715
|
)
|
(125
|
)
|
||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
68,862
|
69,397
|
24,162
|
20,576
|
||||||||||||
Selling and marketing
|
7,875
|
20,834
|
2,494
|
3,652
|
||||||||||||
General and administrative
|
14,341
|
30,179
|
4,597
|
5,753
|
||||||||||||
Total operating expenses
|
91,078
|
120,410
|
31,253
|
29,981
|
||||||||||||
Operating loss
|
(97,306
|
)
|
(122,336
|
)
|
(34,968
|
)
|
(30,106
|
)
|
||||||||
Financial income, net
|
4,852
|
2,827
|
812
|
3,735
|
||||||||||||
Loss before taxes on income
|
(92,454
|
)
|
(119,509
|
)
|
(34,156
|
)
|
(26,371
|
)
|
||||||||
Taxes on income
|
(97
|
)
|
(132
|
)
|
(49
|
)
|
(60
|
)
|
||||||||
Net loss
|
$
|
(92,551
|
)
|
$
|
(119,641
|
)
|
$
|
(34,205
|
)
|
$
|
(26,431
|
)
|
||||
Basic and diluted net loss per ordinary share
|
$
|
(0.69
|
)
|
$
|
(1.35
|
)
|
$
|
(0.25
|
)
|
$
|
(0.20
|
)
|
||||
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share
|
134,939,362
|
92,115,826
|
135,602,409
|
133,430,689
|
September 30,
|
December 31,
|
|||||||
2022
|
2021
|
|||||||
(Unaudited)
|
||||||||
ASSETS
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$
|
32,593
|
$
|
23,640
|
||||
Short term restricted cash
|
723
|
901
|
||||||
Bank deposits
|
135,546
|
230,483
|
||||||
Marketable securities
|
34,602
|
11,607
|
||||||
Trade receivables
|
778
|
513
|
||||||
Inventory
|
4,708
|
4,256
|
||||||
Prepaid expenses and other current assets
|
3,254
|
3,029
|
||||||
Total current assets
|
212,204
|
274,429
|
||||||
LONG-TERM ASSETS:
|
||||||||
Marketable securities
|
14,450
|
38,289
|
||||||
Restricted deposits
|
2,509
|
-
|
||||||
Property and equipment, net
|
28,246
|
14,502
|
||||||
Operating lease right-of-use assets, net
|
26,523
|
-
|
||||||
Total long-term assets
|
71,728
|
52,791
|
||||||
Total assets
|
$
|
283,932
|
$
|
327,220
|
||||
CURRENT LIABILITIES:
|
||||||||
Trade payables
|
$
|
5,383
|
$
|
5,764
|
||||
Advances from customers and deferred revenues
|
1,243
|
196
|
||||||
Employees and payroll accruals
|
9,879
|
8,997
|
||||||
Accrued expenses and other current liabilities
|
8,969
|
6,708
|
||||||
Operating lease liabilities
|
2,557
|
-
|
||||||
Total current liabilities
|
28,031
|
21,665
|
||||||
LONG-TERM LIABILITIES:
|
||||||||
Advances from customers and deferred revenues
|
3,804
|
4,517
|
||||||
Other liabilities
|
-
|
597
|
||||||
Operating lease liabilities
|
29,913
|
-
|
||||||
Warrants liability
|
1,275
|
1,639
|
||||||
Total long-term liabilities
|
34,992
|
6,753
|
||||||
SHAREHOLDERS' EQUITY:
|
||||||||
Ordinary Shares of no-par value
|
-
|
-
|
||||||
Additional paid-in capital
|
698,422
|
683,764
|
||||||
Accumulated deficit
|
(477,513
|
)
|
(384,962
|
)
|
||||
Total shareholders' equity
|
220,909
|
298,802
|
||||||
Total liabilities and shareholders' equity
|
$
|
283,932
|
$
|
327,220
|
Nine Months Ended
September 30,
|
Three Months Ended
September 30,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
|||||||||||||||
Cash flows from operating activities:
|
||||||||||||||||
Net loss
|
$
|
(92,551
|
)
|
$
|
(119,641
|
)
|
$
|
(34,205
|
)
|
$
|
(26,431
|
)
|
||||
Adjustments required to reconcile net loss to net cash used in operating activities:
|
||||||||||||||||
Depreciation and amortization
|
5,929
|
2,024
|
1,737
|
699
|
||||||||||||
Remeasurement of warrants liability
|
(335
|
)
|
(2,744
|
)
|
454
|
(3,589
|
)
|
|||||||||
Increase in accrued interest on bank deposits
|
(567
|
)
|
-
|
(322
|
)
|
-
|
||||||||||
Remeasurement of marketable securities
|
844
|
-
|
137
|
-
|
||||||||||||
Share-based compensation
|
14,097
|
59,827
|
4,932
|
8,165
|
||||||||||||
Foreign exchange loss (gain), net
|
1,421
|
(137
|
)
|
201
|
(80
|
)
|
||||||||||
Decrease (increase) in prepaid expenses and other assets
|
(289
|
)
|
(1,136
|
)
|
2,897
|
4,612
|
||||||||||
Decrease (increase) in trade receivables
|
(265
|
)
|
1,373
|
297
|
866
|
|||||||||||
Increase in inventory
|
(452
|
)
|
(2,447
|
)
|
(57
|
)
|
(947
|
)
|
||||||||
Changes in operating lease assets and liabilities, net
|
5,483
|
-
|
5,913
|
-
|
||||||||||||
Decrease in trade payables
|
(381
|
)
|
(4,361
|
)
|
(441
|
)
|
(7,131
|
)
|
||||||||
Increase in accrued expenses and other liabilities
|
283
|
1,344
|
1,468
|
474
|
||||||||||||
Increase (decrease) in employees and payroll accruals
|
882
|
2,143
|
1,440
|
(2,019
|
)
|
|||||||||||
Increase (decrease) in advances from customers and deferred revenues
|
334
|
570
|
91
|
(968
|
)
|
|||||||||||
Net cash used in operating activities
|
(65,567
|
)
|
(63,185
|
)
|
(15,458
|
)
|
(26,349
|
)
|
||||||||
Cash flows from investing activities:
|
||||||||||||||||
Purchase of property and equipment
|
(17,739
|
)
|
(2,998
|
)
|
(12,713
|
)
|
(864
|
)
|
||||||||
Investment in bank deposits
|
(79,500
|
)
|
(215,000
|
)
|
(29,500
|
)
|
(20,000
|
)
|
||||||||
Withdrawal of bank deposits
|
175,000
|
30,000
|
40,000
|
30,000
|
||||||||||||
Decrease (increase) in restricted deposits
|
(2,633
|
)
|
56
|
(53
|
)
|
55
|
||||||||||
Net cash provided by (used in) investing activities
|
|
75,128
|
|
(187,942
|
)
|
(2,266
|
)
|
9,191
|
||||||||
Cash flows from financing activities:
|
||||||||||||||||
Cash received from Transactions, net of issuance cost
|
-
|
122,728
|
-
|
-
|
||||||||||||
Issuance of ordinary shares, net of issuance cost
|
-
|
217,343
|
-
|
-
|
||||||||||||
Proceeds from exercise of options
|
507
|
690
|
214
|
222
|
||||||||||||
Repayment of loans
|
-
|
(179
|
)
|
-
|
(46
|
)
|
||||||||||
Net cash provided by financing activities
|
507
|
340,582
|
214
|
176
|
||||||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
(1,293
|
)
|
216
|
(171
|
)
|
196
|
||||||||||
Increase (decrease) in cash, cash equivalents and restricted cash
|
8,775
|
89,671
|
(17,681
|
)
|
(16,786
|
)
|
||||||||||
Cash, cash equivalents and restricted cash at beginning of the period
|
24,541
|
50,766
|
50,997
|
157,223
|
||||||||||||
Cash, cash equivalents and restricted cash at end of the period
|
$
|
33,316
|
$
|
140,437
|
$
|
33,316
|
$
|
140,437
|